Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, has announced it will report its third quarter 2024 financial results after market close on October 31, 2024. Following this, the company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the financial results and provide a corporate update.
Zymeworks develops a diverse pipeline of novel, multifunctional biotherapeutics aimed at improving the standard of care for difficult-to-treat diseases. The event will be webcast live, and both dial-in details and webcast replays will be available on the company's investor relations website at https://ir.zymeworks.com/events-and-presentations.
Zymeworks Inc. (Nasdaq: ZYME), una compagnia di biotecnologia in fase clinica, ha annunciato che riporterà i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato il 31 ottobre 2024. Successivamente, la società ospiterà una conferenza telefonica e una diretta web alle 16:30 ora orientale dello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Zymeworks sviluppa una pipeline diversificata di bioterapeutiche innovative e multifunzionali mirate a migliorare gli standard di cura per malattie difficili da trattare. L'evento sarà trasmesso in diretta, e i dettagli per partecipare telefonicamente e le riprese della diretta saranno disponibili sul sito delle relazioni con gli investitori della società all'indirizzo https://ir.zymeworks.com/events-and-presentations.
Zymeworks Inc. (Nasdaq: ZYME), una compañía de biotecnología en etapa clínica, ha anunciado que reportará sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el 31 de octubre de 2024. Después de esto, la compañía llevará a cabo una llamada de conferencia y una transmisión web a las 4:30 PM, hora del este del mismo día para discutir los resultados financieros y proporcionar una actualización corporativa.
Zymeworks desarrolla un pipeline diverso de bioterapéuticas novedosas y multifuncionales destinadas a mejorar el estándar de atención para enfermedades difíciles de tratar. El evento será transmitido en vivo, y tanto los detalles para unirse por teléfono como las repeticiones de la transmisión web estarán disponibles en el sitio web de relaciones con inversores de la compañía en https://ir.zymeworks.com/events-and-presentations.
재무정보 기업 Zymeworks Inc. (Nasdaq: ZYME)가 2024년 3분기 재무 결과를 2024년 10월 31일 주식 시장 마감 이후 발표할 것이라고 발표했습니다. 이후 회사는 당일 동부 표준시 오후 4시 30분에 재무 결과를 논의하고 기업 업데이트를 제공하기 위한 전화 회의 및 웹 캐스트를 주최할 예정입니다.
Zymeworks는 치료하기 어려운 질병에 대한 치료 기준을 향상시키기 위해 독창적이고 다기능적인 생물 치료제의 다양한 파이프라인을 개발하고 있습니다. 해당 이벤트는 생중계될 예정이며, 전화 접속 세부사항 및 웹캐스트 재방송은 회사의 투자자 관계 웹사이트 https://ir.zymeworks.com/events-and-presentations에서 확인할 수 있습니다.
Zymeworks Inc. (Nasdaq: ZYME), une entreprise de biotechnologie en phase clinique, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 après la fermeture du marché le 31 octobre 2024. Par la suite, l'entreprise tiendra une conférence téléphonique et un webinaire à 16h30, heure de l'Est le même jour pour discuter des résultats financiers et fournir une mise à jour corporate.
Zymeworks développe un pipeline diversifié de biothérapeutiques innovantes et multifonctionnelles visant à améliorer le standard de soin pour les maladies difficiles à traiter. L'événement sera diffusé en direct, et les détails pour se connecter par téléphone ainsi que les rediffusions du webinaire seront disponibles sur le site des relations investisseurs de l'entreprise à l'adresse https://ir.zymeworks.com/events-and-presentations.
Zymeworks Inc. (Nasdaq: ZYME), ein biotechnologisches Unternehmen in der klinischen Phase, hat angekündigt, dass es seine Finanzberichte für das dritte Quartal 2024 nach Marktschluss am 31. Oktober 2024 veröffentlichen wird. Anschließend wird das Unternehmen am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Finanzberichte zu besprechen und ein Unternehmensupdate zu geben.
Zymeworks entwickelt ein diverses Portfolio neuartiger, multifunktionaler Biotherapeutika, die darauf abzielen, den Behandlungsstandard für schwer behandelbare Krankheiten zu verbessern. Die Veranstaltung wird live übertragen, und sowohl die Telefonkonferenzdetails als auch die Wiederholungen des Webcasts sind auf der Website der Investorenbeziehungen des Unternehmens unter https://ir.zymeworks.com/events-and-presentations verfügbar.
- None.
- None.
VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).
The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China.
Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks (ZYME) report its Q3 2024 financial results?
What time is Zymeworks' (ZYME) Q3 2024 earnings call scheduled for?
Where can I find the webcast details for Zymeworks' (ZYME) Q3 2024 earnings call?
What does Zymeworks (ZYME) specialize in as a biotechnology company?
